All In Biotech

Drug Trial Radar · NCT02970162

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome

Last checked: Nov 20, 2026Latest source record: Dec 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

26

Actual

Start

Nov 2016

Primary completion

Oct 2017

Study completion Oct 2017

Sponsor

Lead sponsor
Catalyst Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study.

Conditions

  • Lambert-Eaton Myasthenic Syndrome

Interventions

  • Amifampridine PhosphateDrug

  • Placebo Oral TabletDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quantitative Myasthenia Gravis (QMG) ScoreTime frame: change from baseline in QMG score at end of day 4
  2. Subject Global Impression (SGI) ScoreTime frame: change from baseline in SGI score at end of day 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.